Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway

Experimental Cell Research

Volumn 330, Issue 1, 2015, Pages 43-55

  Chen, Xiao qing ^a   Liu, Xu ^a   Wang, Quan xing ^b   Zhang, Ming jian ^b   Guo, Meng ^b   Liu, Fang ^b   Jiang, Wei feng ^a   Zhou, Li ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Atrial fibrosis; Pioglitazone; Signaling pathway

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; PIOGLITAZONE; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; 2,4 THIAZOLIDINEDIONE DERIVATIVE; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANGIOTENSIN II INDUCED ATRIAL FIBROBLAST PROLIFERATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL FIBROSIS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; IN VITRO STUDY; IN VIVO STUDY; INFUSION; MALE; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; DRUG EFFECTS; HEART ATRIUM; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MUS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; FIBROSIS; HEART ATRIA; MALE; MICE; MICE, INBRED C57BL; MYOFIBROBLASTS; NF-KAPPA B; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84916932614     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.08.021     Document Type: Article

References (32)

1. Iwasaki Y.K., Nishida K., Kato T., Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011, 124(20):2264-2274.
2. Tan A.Y., Zimetbaum P. Atrial fibrillation and atrial fibrosis. J. Cardiovasc. Pharmacol. 2011, 57(6):625-629.
3. Verheule S., Sato T., Everett T., Engle S.K., Otten D., Rubart-von der Lohe M., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ. Res. 2004, 94(11):1458-1465.
4. Novo G., Guttilla D., Fazio G., Cooper D., Novo S. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br. J. Clin. Pharmacol. 2008, 66(3):345-351.
5. Kume O., Takahashi N., Wakisaka O., Nagano-Torigoe Y., Teshima Y., Nakagawa M., et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011, 8(2):278-285.
6. Wakisaka O., Takahashi N., Shinohara T., Ooie T., Nakagawa M., Yonemochi H., et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J. Mol. Cell. Cardiol. 2007, 43(5):616-626.
7. Fukunaga N., Takahashi N., Hagiwara S., Kume O., Fukui A., Teshima Y., et al. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role ofoxidative stress. Heart Rhythm 2012, 9(12):2023-2031.
8. Xu D., Murakoshi N., Igarashi M., Hirayama A., Ito Y., Seo Y., et al. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J. Cardiovasc. Electrophysiol. 2012, 23(2):209-217.
9. Shimano M., Tsuji Y., Inden Y., Kitamura K., Uchikawa T., Harata S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008, 5(3):451-459.
10. Sakamoto A., Hongo M., Furuta K., Saito K., Nagai R., Ishizaka N. Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int. J. Cardiol. 2013, 167(2):409-415.
11. Gu J., Liu X., Wang Q.X., Tan H.W., Guo M., Jiang W.F., et al. Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp. Cell Res. 2012, 318(16):2105-2115.
12. Gu J., Liu X., Wang Q.X., Guo M., Liu F., Song Z.P., et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. J. Mol. Cell. Cardiol. 2013, 65:1-8.
13. Tsushima K., Osawa T., Yanai H., Nakajima A., Takaoka A., Manabe I., et al. IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. Faseb J. 2011, 25(5):1531-1543.
14. Burstein B., Qi X.Y., Yeh Y.H., Calderone A., Nattel S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc. Res. 2007, 76(3):442-452.
15. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 2008, 51(8):802-809.
16. Ehrlich J.R., Hohnloser S.H., Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J. 2006, 27(5):512-518.
17. Friedrichs K., Klinke A., Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med. 2011, 17(10):556-563.
18. Omura T., Yoshiyama M., Kim S., Matsumoto R., Nakamura Y., Izumi Y., et al. Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. Arterioscler. Thromb. Vasc. Biol. 2004, 24(2):270-275.
19. Yue L., Xie J., Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 2011, 89(4):744-753.
20. Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011, 79(9):944-956.
21. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15(9):1077-1081.
22. Landström M. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 2010, 42(5):585-589.
23. Doyon P., Servant M.J. Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells. J. Biol. Chem. 2010, 285(40):30708-30718.
24. Watkins S.J., Borthwick G.M., Oakenfull R., Robson A., Arthur H.M. Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent. Hypertens. Res. 2012, 35(4):393-398.
25. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 2003, 171(8):4304-4310.
26. Wakili R., Voigt N., Kääb S., Dobrev D., Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 2011, 121(8):2955-2968.
27. He X., Gao X., Peng L., Wang S., Zhu Y., Ma H., et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ. Res. 2011, 108(2):164-175.
28. Volpi C., Fallarino F., Pallotta M.T., Bianchi R., Vacca C., Belladonna M.L., et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat. Commun. 2013, 4:1852.
29. Akoum N., Daccarett M., McGann C., Segerson N., Vergara G., Kuppahally S., et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J. Cardiovasc. Electrophysiol. 2011, 22(1):16-22.
30. Nattel S., Burstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 2008, 1(1):62-73.
31. Gu J., Liu X., Wang X., Shi H., Tan H., Zhou L., et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011, 13(9):1256-1261.
32. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y.F., et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008, 51(2):296-301.